Integrity (IGAP) 7.0000 $IGAP
Integrity Applications, Inc. Announces Equity Financing of $3.0 Million
PR Newswire - Wed Sep 03, 7:19AM CDT
Integrity Applications, Inc. (OTCQB: IGAP) ("Integrity"
, announced today that, on August 29, 2014, it raised an aggregate of $3,036,000 through the sale in a private placement transaction of 3,036 units (each a "Unit" and, collectively, the "Units" , at a price of $1,000 per Unit. Each Unit consists of: (a) one share of Integrity's newly designated Series B 5.5% Convertible Preferred Stock (the "Series B Preferred Stock" , (b) a five year warrant to purchase, at an exercise price of $5.80 per share, up to such number of shares of Integrity common stock equal to 100% of the shares of Integrity common stock issuable upon conversion of such share of Series B Preferred Stock and (c) a five year warrant to purchase, at an exercise price of $10.00 per share, up to such number of shares of Integrity common stock equal to 100% of the shares of Integrity common stock issuable upon conversion of such share of Series B Preferred Stock.
Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp.
PR Newswire - Mon Jul 21, 7:00AM CDT
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity" , developer of the GlucoTrack® model DF-F noninvasive blood glucose measurement device, announced today that it has entered, through its wholly-owned subsidiary, Integrity Applications Ltd., into a Manufacturing Agreement with Wistron Corp, the manufacturing arm of Acer Inc. Pursuant to the agreement, Wistron has agreed to manufacture and service (on a non-exclusive basis) the GlucoTrack Model DF-F and any future products, if any, introduced by the Company. Wistron has agreed to provide full turn-key manufacturing services for the GlucoTrack model DF-F, including components procurement, units assembly, device integration, testing and packaging.
Integrity Applications, Inc. Announces Adjournment of Annual Meeting
PR Newswire - Wed Jul 09, 9:10AM CDT
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity" , developer of the GlucoTrack model DF-F noninvasive blood glucose measurement device, announced today that its annual meeting of stockholders scheduled for, and convened on July 8, 2014, was adjourned due to the lack of requisite quorum. Only stockholders of record on the record date, May 20, 2014, are entitled to and are being requested to vote.
Integrity Applications, Inc. announces first wholesale orders for its GlucoTrack® model DF-F glucose measurement device and the hiring of a Director of Marketing and Sales
PR Newswire - Wed Jul 02, 7:39AM CDT
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity" , developer of the GlucoTrack model DF-F noninvasive blood glucose measurement device, announced today that it has, through its wholly-owned subsidiary, Integrity Applications Ltd., recently received its first wholesale purchase orders for its GlucoTrack model DF-F.
Integrity Applications Signs Two Additional Distribution Agreements for Its GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Thu Mar 20, 8:23AM CDT
Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack(R) model DF-F noninvasive blood glucose measurement device, has entered, through its wholly-owned subsidiary, Integrity Applications Ltd., into distribution agreements for the GlucoTrack device in the Philippines and in Chile. According to the International Diabetes Federation, a total of about 3.3 million people with diabetes, or 6 percent of the adult population, live in the Philippines, and a total of about 1.3 million people with diabetes, or 10.4 percent of the adult population, live in Chile. This is its second distribution agreement in Asia and the second distribution agreement in South America.
Integrity Applications Receives CE Mark Approval for Six-Month Calibration Validity of GlucoTrack(R) DF-F
Business Wire - Mon Mar 17, 6:30AM CDT
Integrity Applications, Inc. (OTCQB:IGAP), developer of the GlucoTrack(R) model DF-F noninvasive blood glucose measurement device, received CE Mark approval from Dekra Certification B.V., its Notified Body in the European Union, to extend its claim from a monthly recalibration to a six-month calibration validity of the GlucoTrack model DF-F device.
CORRECTING and REPLACING Integrity Applications Signs Three Additional Distribution Agreements for Its GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Mon Mar 10, 9:39AM CDT
--Also Secures Distribution Agreements for Thailand and Uruguay
Integrity Applications Signs Three Additional Distribution Agreements for Its GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Mon Mar 10, 6:30AM CDT
--Also Secures Distribution Agreements for Thailand and Uruguay
Integrity Applications Signs Third Distribution Agreement for GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Wed Jan 29, 6:30AM CST
Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack(R) model DF-F noninvasive blood glucose measurement device, has entered, through its subsidiary company, Integrity Applications Ltd., into a distribution agreement appointing Felkasta JSC as the exclusive distributor of the GlucoTrack device in Lithuania, Latvia, Estonia and Belarus effective March 28, 2014. According to the International Diabetes Federation, a total of 281,000 people with diabetes live in Lithuania, Latvia and Estonia combined, while 445,000 people with diabetes live in Belarus.
Integrity Applications Signs Additional Distribution Agreement for GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Tue Jan 14, 6:00AM CST
Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack(R) model DF-F non-invasive blood glucose measurement device, has entered into a distribution agreement appointing Kocak Medical & Laboratory Technology Ltd. as the exclusive distributor of the GlucoTrack device in Turkey effective February 14, 2014. According to the International Diabetes Federation, more than 7 million diabetes patients live in Turkey, representing approximately 15 percent of the nation's adult population.
Integrity Applications Signs Distribution Agreement for GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Mon Jan 13, 6:00AM CST
Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack(R) model DF-F non-invasive blood glucose measurement device, has entered into a distribution agreement appointing Ultramedix Australasia Pty Ltd., with their depth of specialist clinical expertise and expertise in engineering, sales and marketing in the high-tech medical industry, as the exclusive distributor of the GlucoTrack device in Australia and New Zealand. The appointment is subject to, and will take effect 14 days after, the approval of the listing of the GlucoTrack model DF-F device on the Australian Register of Therapeutic Goods (ARTG) register. According to the International Diabetes Federation, nearly 2 million diabetes patients live in Australia and New Zealand combined.
Integrity Applications to Present at the Sidoti & Company Semi-Annual Micro-Cap Conference in New York City on January 13, 2014
Business Wire - Wed Jan 08, 6:59AM CST
Integrity Applications, Inc. (OTCQB:IGAP), developer of the GlucoTrack(R) model DF-F non-invasive blood glucose measurement device, today announced that Avner Gal, its President and CEO, will be presenting at Sidoti & Company's Semi-Annual Micro-Cap Conference at the Grand Hyatt Hotel in New York, New York on Monday, January 13, 2014. He is scheduled to present at 11:20 AM ET in the Estate 2 Room.
S&P Capital IQ Initiates Coverage on Integrity Applications, Inc. in Standard & Poor's Factual Stock Reports
PR Newswire - Wed Jul 03, 8:00AM CDT
S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Integrity Applications, Inc.
Integrity Applications to Present at the Sidoti & Company Semi-Annual Microcap Conference
Business Wire - Wed Jun 05, 12:21PM CDT
Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack DF-F non-invasive blood glucose measurement device, announced today that Avner Gal, its President and Chief Executive Officer, is scheduled to present a corporate overview at the Sidoti & Co., LLC Semi-Annual Microcap Conference at 2:40 p.m., Eastern Time, on June 7, 2013. The conference is being held at the Grand Hyatt Hotel in New York City.
Integrity Applications Receives CE Mark Approval for Its GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Tue Jun 04, 6:30AM CDT
Integrity Applications, Inc. (OTC/QB: IGAP) announced today that it has received CE Mark approval for its GlucoTrack(R) DF-F non-invasive blood glucose measurement device. Receipt of the CE Mark allows Integrity Applications to market and sell the GlucoTrack DF-F glucose monitoring device in European Union (EU) member countries that have adopted the MDD without being subject to additional national regulations with regard to demonstration of performance and safety (although certain EU member countries may request or require additional performance and/or safety data from time to time, on a case-by-case basis). The CE mark also permits the sale in countries that have an MDD Mutual Recognition Agreement with the EU.
Integrity Applications Common Stock is Publicly Quoted on the OTC Bulletin Board under the Symbol "IGAP"
Business Wire - Tue Apr 09, 7:00AM CDT
Integrity Applications, Inc. (OTCQB:IGAP), developer of the GlucoTrack DF-F non-invasive blood glucose measurement device, announced that its common stock is now publicly quoted on the OTC Bulletin Board under the symbol IGAP. Investors will be able to view the Real Time Level II stock quotes for IGAP at www.otcmarkets.com/stock/igap/quote.
Integrity Applications, Inc. Announces Equity Financing of $3.0 Million
PR Newswire - Wed Sep 03, 7:19AM CDT
Integrity Applications, Inc. (OTCQB: IGAP) ("Integrity"
, announced today that, on August 29, 2014, it raised an aggregate of $3,036,000 through the sale in a private placement transaction of 3,036 units (each a "Unit" and, collectively, the "Units" , at a price of $1,000 per Unit. Each Unit consists of: (a) one share of Integrity's newly designated Series B 5.5% Convertible Preferred Stock (the "Series B Preferred Stock" , (b) a five year warrant to purchase, at an exercise price of $5.80 per share, up to such number of shares of Integrity common stock equal to 100% of the shares of Integrity common stock issuable upon conversion of such share of Series B Preferred Stock and (c) a five year warrant to purchase, at an exercise price of $10.00 per share, up to such number of shares of Integrity common stock equal to 100% of the shares of Integrity common stock issuable upon conversion of such share of Series B Preferred Stock. Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp.
PR Newswire - Mon Jul 21, 7:00AM CDT
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity"
, developer of the GlucoTrack® model DF-F noninvasive blood glucose measurement device, announced today that it has entered, through its wholly-owned subsidiary, Integrity Applications Ltd., into a Manufacturing Agreement with Wistron Corp, the manufacturing arm of Acer Inc. Pursuant to the agreement, Wistron has agreed to manufacture and service (on a non-exclusive basis) the GlucoTrack Model DF-F and any future products, if any, introduced by the Company. Wistron has agreed to provide full turn-key manufacturing services for the GlucoTrack model DF-F, including components procurement, units assembly, device integration, testing and packaging. Integrity Applications, Inc. Announces Adjournment of Annual Meeting
PR Newswire - Wed Jul 09, 9:10AM CDT
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity"
, developer of the GlucoTrack model DF-F noninvasive blood glucose measurement device, announced today that its annual meeting of stockholders scheduled for, and convened on July 8, 2014, was adjourned due to the lack of requisite quorum. Only stockholders of record on the record date, May 20, 2014, are entitled to and are being requested to vote. Integrity Applications, Inc. announces first wholesale orders for its GlucoTrack® model DF-F glucose measurement device and the hiring of a Director of Marketing and Sales
PR Newswire - Wed Jul 02, 7:39AM CDT
Integrity Applications, Inc. (OTCQB: IGAP) (the "Company" or "Integrity"
, developer of the GlucoTrack model DF-F noninvasive blood glucose measurement device, announced today that it has, through its wholly-owned subsidiary, Integrity Applications Ltd., recently received its first wholesale purchase orders for its GlucoTrack model DF-F. Integrity Applications Signs Two Additional Distribution Agreements for Its GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Thu Mar 20, 8:23AM CDT
Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack(R) model DF-F noninvasive blood glucose measurement device, has entered, through its wholly-owned subsidiary, Integrity Applications Ltd., into distribution agreements for the GlucoTrack device in the Philippines and in Chile. According to the International Diabetes Federation, a total of about 3.3 million people with diabetes, or 6 percent of the adult population, live in the Philippines, and a total of about 1.3 million people with diabetes, or 10.4 percent of the adult population, live in Chile. This is its second distribution agreement in Asia and the second distribution agreement in South America.
Integrity Applications Receives CE Mark Approval for Six-Month Calibration Validity of GlucoTrack(R) DF-F
Business Wire - Mon Mar 17, 6:30AM CDT
Integrity Applications, Inc. (OTCQB:IGAP), developer of the GlucoTrack(R) model DF-F noninvasive blood glucose measurement device, received CE Mark approval from Dekra Certification B.V., its Notified Body in the European Union, to extend its claim from a monthly recalibration to a six-month calibration validity of the GlucoTrack model DF-F device.
CORRECTING and REPLACING Integrity Applications Signs Three Additional Distribution Agreements for Its GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Mon Mar 10, 9:39AM CDT
--Also Secures Distribution Agreements for Thailand and Uruguay
Integrity Applications Signs Three Additional Distribution Agreements for Its GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Mon Mar 10, 6:30AM CDT
--Also Secures Distribution Agreements for Thailand and Uruguay
Integrity Applications Signs Third Distribution Agreement for GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Wed Jan 29, 6:30AM CST
Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack(R) model DF-F noninvasive blood glucose measurement device, has entered, through its subsidiary company, Integrity Applications Ltd., into a distribution agreement appointing Felkasta JSC as the exclusive distributor of the GlucoTrack device in Lithuania, Latvia, Estonia and Belarus effective March 28, 2014. According to the International Diabetes Federation, a total of 281,000 people with diabetes live in Lithuania, Latvia and Estonia combined, while 445,000 people with diabetes live in Belarus.
Integrity Applications Signs Additional Distribution Agreement for GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Tue Jan 14, 6:00AM CST
Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack(R) model DF-F non-invasive blood glucose measurement device, has entered into a distribution agreement appointing Kocak Medical & Laboratory Technology Ltd. as the exclusive distributor of the GlucoTrack device in Turkey effective February 14, 2014. According to the International Diabetes Federation, more than 7 million diabetes patients live in Turkey, representing approximately 15 percent of the nation's adult population.
Integrity Applications Signs Distribution Agreement for GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Mon Jan 13, 6:00AM CST
Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack(R) model DF-F non-invasive blood glucose measurement device, has entered into a distribution agreement appointing Ultramedix Australasia Pty Ltd., with their depth of specialist clinical expertise and expertise in engineering, sales and marketing in the high-tech medical industry, as the exclusive distributor of the GlucoTrack device in Australia and New Zealand. The appointment is subject to, and will take effect 14 days after, the approval of the listing of the GlucoTrack model DF-F device on the Australian Register of Therapeutic Goods (ARTG) register. According to the International Diabetes Federation, nearly 2 million diabetes patients live in Australia and New Zealand combined.
Integrity Applications to Present at the Sidoti & Company Semi-Annual Micro-Cap Conference in New York City on January 13, 2014
Business Wire - Wed Jan 08, 6:59AM CST
Integrity Applications, Inc. (OTCQB:IGAP), developer of the GlucoTrack(R) model DF-F non-invasive blood glucose measurement device, today announced that Avner Gal, its President and CEO, will be presenting at Sidoti & Company's Semi-Annual Micro-Cap Conference at the Grand Hyatt Hotel in New York, New York on Monday, January 13, 2014. He is scheduled to present at 11:20 AM ET in the Estate 2 Room.
S&P Capital IQ Initiates Coverage on Integrity Applications, Inc. in Standard & Poor's Factual Stock Reports
PR Newswire - Wed Jul 03, 8:00AM CDT
S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Integrity Applications, Inc.
Integrity Applications to Present at the Sidoti & Company Semi-Annual Microcap Conference
Business Wire - Wed Jun 05, 12:21PM CDT
Integrity Applications, Inc. (OTCQB: IGAP), developer of the GlucoTrack DF-F non-invasive blood glucose measurement device, announced today that Avner Gal, its President and Chief Executive Officer, is scheduled to present a corporate overview at the Sidoti & Co., LLC Semi-Annual Microcap Conference at 2:40 p.m., Eastern Time, on June 7, 2013. The conference is being held at the Grand Hyatt Hotel in New York City.
Integrity Applications Receives CE Mark Approval for Its GlucoTrack(R) Model DF-F Glucose Monitoring Device
Business Wire - Tue Jun 04, 6:30AM CDT
Integrity Applications, Inc. (OTC/QB: IGAP) announced today that it has received CE Mark approval for its GlucoTrack(R) DF-F non-invasive blood glucose measurement device. Receipt of the CE Mark allows Integrity Applications to market and sell the GlucoTrack DF-F glucose monitoring device in European Union (EU) member countries that have adopted the MDD without being subject to additional national regulations with regard to demonstration of performance and safety (although certain EU member countries may request or require additional performance and/or safety data from time to time, on a case-by-case basis). The CE mark also permits the sale in countries that have an MDD Mutual Recognition Agreement with the EU.
Integrity Applications Common Stock is Publicly Quoted on the OTC Bulletin Board under the Symbol "IGAP"
Business Wire - Tue Apr 09, 7:00AM CDT
Integrity Applications, Inc. (OTCQB:IGAP), developer of the GlucoTrack DF-F non-invasive blood glucose measurement device, announced that its common stock is now publicly quoted on the OTC Bulletin Board under the symbol IGAP. Investors will be able to view the Real Time Level II stock quotes for IGAP at www.otcmarkets.com/stock/igap/quote.
